Posted on 16/05/2012 in Medical Company Product News

The device has been granted CE Mark ratification after demonstrating its safety and efficacy in reducing blood pressure among hypertension patients in recent clinical trials.

EnligHTN represents the first multi-electrode technology developed for renal denervation, allowing a consistent and predictable pattern of four ablations to be delivered at 90-second intervals.

It offers benefits such as improved consistency and procedural reliability, as well as being easier to incorporate into workflows and providing cost-effectiveness benefits.

Frank Callaghan, president of the organisation's cardiovascular division, said: "St Jude Medical is focused on improving patient care while reducing the economic burden of epidemic diseases and our groundbreaking EnligHTN renal denervation system is a great example of that focus."

The EnligHTN range and Portico line of transcatheter heart valves were identified by St Jude Medical's chief executive officer Daniel Starks last month as crucial parts of the company's efforts to build on its strong start to the current fiscal year.

Other news stories from 16/05/2012

• Allergan receives NICE backing for Botox migraine treatment
• Bristol-Myers Squibb and Tsinghua University announce partnership
• Bayer HealthCare pays milestone fee to Maxygen
• GlaxoSmithKline announces acquisition of Cellzome
• Future Science Group assists publication of new cell therapy glossary
• St Jude Medical launches EnligHTN renal denervation system
• Covidien finalises superDimension takeover
• Consultation launched on new health labelling for food packaging
• Dr Reddy's sees strong growth in 2012 business year
• Lab21 secures hepatitis C drug resistance patents
• Lung lining cells 'can improve cancer diagnosis'
• Heraeus launches Venus Pearl dental composite

Read more in the Zenopa News Archive

How this news is generated

...